Barclays
COGT icon

Barclays’s Cogent Biosciences COGT Stock Holding History

Barclays’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.98M Buy
217,977
+170,014
+354% +$6.28M ﹤0.01% 1862
2026
Q2 		$1.86M Buy
47,963
+16,702
+53% +$584K ﹤0.01% 2387
2026
Q1 		$1.2M Sell
31,261
-290,345
-90% -$10.7M ﹤0.01% 2639
2025
Q4 		$11.4M Sell
321,606
-38,224
-11% -$1.07M ﹤0.01% 1586
2025
Q3 		$5.17M Buy
359,830
+39,265
+12% +$465K ﹤0.01% 2169
2025
Q2 		$2.3M Buy
320,565
+145,647
+83% +$807K ﹤0.01% 2740
2025
Q1 		$1.05M Sell
174,918
-18,150
-9% -$142K ﹤0.01% 3079
2024
Q4 		$1.51M Buy
193,068
+17,384
+10% +$173K ﹤0.01% 3105
2024
Q3 		$1.9M Buy
175,684
+97,541
+125% +$950K ﹤0.01% 2895
2024
Q2 		$659K Sell
78,143
-29,510
-27% -$224K ﹤0.01% 2863
2024
Q1 		$723K Sell
107,653
-121,552
-53% -$751K ﹤0.01% 3348
2023
Q4 		$1.35M Buy
229,205
+118,293
+107% +$906K ﹤0.01% 3218
2023
Q3 		$1.08M Sell
110,912
-1,481
-1% -$17.6K ﹤0.01% 2280
2023
Q2 		$1.33M Buy
112,393
+4,595
+4% +$52.7K ﹤0.01% 2130
2023
Q1 		$1.16M Sell
107,798
-71,694
-40% -$917K ﹤0.01% 2621
2022
Q4 		$2.07M Buy
179,492
+31,236
+21% +$387K ﹤0.01% 2238
2022
Q3 		$2.21M Buy
148,256
+145,473
+5,227% +$1.99M ﹤0.01% 1683
2022
Q2 		$25K Sell
2,783
-31,359
-92% -$214K ﹤0.01% 4306
2022
Q1 		$257K Buy
+34,142
New +$238K ﹤0.01% 3272
2020
Q3 		– Sell
-1,869
Closed -$3K – 5259
2020
Q2 		$3K Buy
+1,869
New +$3.47K ﹤0.01% 5419
2020
Q1 		– Sell
-6,338
Closed -$18K – 6172
2019
Q4 		$18K Sell
6,338
-261
-4% -$1.06K ﹤0.01% 6000
2019
Q3 		$38K Sell
6,599
-7,958
-55% -$64.7K ﹤0.01% 6013
2019
Q2 		$152K Buy
14,557
+13,120
+913% +$175K ﹤0.01% 5347
2019
Q1 		$25K Buy
+1,437
New +$24.6K ﹤0.01% 6260
2018
Q4 		– Sell
-1,587
Closed -$65K – 6982
2018
Q3 		$65K Buy
1,587
+1,522
+2,342% +$85.8K ﹤0.01% 5893
2018
Q2 		$4K Buy
+65
New +$3.12K ﹤0.01% 6732

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Barclays's COGT Position: Q3 2026 in Review

Barclays increased its Cogent Biosciences (COGT) stake by 354% in Q3 2026, buying an estimated $6.28M and bringing the position to 217,977 shares worth $6.98M. The position accounts for ﹤0.01% of the portfolio, ranked #1862.

Barclays first reported a position in COGT in Q2 2018 and has held it in 26 quarters since. The position peaked at $11.4M in Q4 2025. 202 funds tracked by Wall St. Rank hold COGT as of Q3 2026.

  • Barclays held 217,977 shares of Cogent Biosciences worth $6.98M as of Q3 2026.
  • Barclays bought 170,014 Cogent Biosciences shares in Q3 2026, an estimated $6.28M.
  • Cogent Biosciences made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1862 holding.
  • Barclays first reported a position in Cogent Biosciences in Q2 2018 and has held it in 26 quarters since.
  • Barclays's Cogent Biosciences position peaked at $11.4M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.